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Case Report
A case of recurrent epilepsy-associated rosette-forming
glioneuronal tumor with anaplastic transformation in
the absence of therapy
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Kellie Nazemi,1 Arie Perry,2 David A. Solomon,2 Sakir H. Gultekin,1,3 Stephen Moore,1
Susan Olson,1 Helen Lawce,1 Lora Lucas,1 Christopher L. Corless1 and Matthew D. Wood1
1Department of Pathology, Oregon Health & Science University, Portland, Oregon, 2Department of Pathology,
University of California, San Francisco, San Francisco, California and 3Department of Pathology and Laboratory
Medicine,University of Miami, Holtz Children’s Hospital, Miami, Florida, USA
Rosette-forming glioneuronal tumor (RGNT) most com-
monly occurs adjacent to the fourth ventricle and therefore
rarely presents with epilepsy. Recent reports describe
RGNT occurrence in other anatomical locations with con-
siderable morphologic and genetic overlap with the
epilepsy-associated dysembryoplastic neuroepithelial tumor
(DNET). Examples of RGNT or DNET with anaplastic
change are rare, and typically occur in the setting of radia-
tion treatment. We present the case of a 5-year-old girl with
seizures, who underwent near total resection of a cystic
temporal lobe lesion. Pathology showed morphologic and
immunohistochemical features of RGNT, albeit with focally
overlapping DNET-like patterns. Resections of residual or
recurrent tumor were performed 1 year and 5 years after
the initial resection, but no adjuvant radiation or chemo-
therapy was given. Ten years after the initial resection, sur-
veillance imaging identified new and enhancing nodules,
leading to another gross total resection. This specimen
showed areas similar to the original tumor, but also high-
grade foci with oligodendroglial morphology, increased cel-
lularity, palisading necrosis, microvascular proliferation,
and up to 13 mitotic figures per 10 high power fields. Ancil-
lary studies the status by sequencing showed wild-type of
the isocitrate dehydrogenase 1 (IDH1), IDH2, and human
histone 3.3 (H3F3A) genes, and BRAF studies were nega-
tive for mutation or rearrangement. Fluorescence in situ
hybridization (FISH) showed codeletion of 1p and 19q
limited to the high-grade regions. By immunohistochemis-
try there was loss of nuclear alpha-thalassemia mental retar-
dation syndrome, X-linked (ATRX) expression only in the
high-grade region. Next-generation sequencing showed an
fibroblast growth factor receptor receptor 1 (FGFR1)
kinase domain internal tandem duplication in three re-
section specimens. ATRX mutation in the high-grade tumor
was confirmed by sequencing which showed a frameshift
mutation (p.R1427fs), while the apparent 1p/19q-codeletion
by FISH was due to loss of chromosome arm 1p and only
partial loss of 19q. Exceptional features of this case include
the temporal lobe location, 1p/19q loss by FISH without
true whole-arm codeletion, and anaplastic transformation
associated with ATRX mutation without radiation or
chemotherapy.
Key words: 1p/19q-codeletion, anaplastic transformation,
ATRX, fibroblast growth factor receptor receptor
1 (FGFR1) kinase domain internal tandem duplication,
rosette-forming glioneuronal tumor (RGNT).
INTRODUCTION
Rosette-forming glioneuronal tumor (RGNT) is a WHO
grade I neoplasm usually occurring adjacent to or within
the fourth ventricle, but is also described in other anatomic
locations.1–4 Histologic findings include two distinct mor-
phologic components, one exhibiting neurocytic rosettes or
perivascular pseudorosettes, and another component with
fibrillary astrocytic cells similar to pilocytic astrocytoma.5
Characteristic molecular alterations include activating
mutations in the phosphatidylinositol-4,5-bisphosphate
3-kinase, catalytic subunit alpha gene (PIK3CA) structural
rearrangements or activating mutations in the fibroblast
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growh factor receptor 1 gene (FGFR1), although these are
not specific to RGNT.6 Some examples show morphologic
and genetic overlap with dysembryoplastic neuroepithelial
tumor (DNET), and this differential diagnosis can be chal-
lenging.7 RGNTs are rarely reported to undergo anaplastic
change, with most examples occurring in association with
radiation treatment.2,3 In the central nervous system, alpha-
thalassemia with mental retardation syndrome, X-linked
gene (ATRX) mutations are typically associated with infil-
trating astrocytomas with IDH gene mutations, and are also
frequently seen in high-grade gliomas with histone H3
p.K27M and H3.3 p.G34R or p.G34V mutations.8 More
recently, ATRX mutations have been associated with high-
grade transformation in tumors histologically categorized as
pilocytic astrocytomas.9 Here, we report a case of a recur-
rent epilepsy-associated tumor histologically compatible
with RGNT that showed anaplastic transformation and
acquisition of anATRXmutation in the absence of radiation
or chemotherapy.
CLINICAL SUMMARY AND PATHOLOGIC
FINDINGS
A 1-year-old girl presented with developmental delay
and seizures. Magnetic resonance imaging (MRI) identi-
fied a cystic temporal lesion (Fig. 1A). She was moni-
tored by imaging until age 5, when new enhancement
and growth of the lesion prompted a near total surgical
resection. Histopathological findings were observed on
the resected tissuesections stained with hematoxylin and
eosin (HE). This specimen showed a moderately cellular
neoplasm of monomorphic cells with round nuclei,
perinuclear halos, a mucin-rich background, and
neurocytic rosettes (Fig. 1B). Other areas showed piloid
cells with long thin processes and spindled nuclei
(Fig. 1C). Synaptophysin immunoreactivity was intense
and highlighted neuropil cores within the rosettes
(Fig. 1D). Floating neurons and nodular architecture
were not identified. The pathologic diagnosis at the initial
resection was extraventricular neurocytoma with a focal
DNET-like pattern, WHO grade II.
This patient subsequently underwent surgical gross
total resection (GTR) of residual tumor at age 6, prompted
by worsening epilepsy, and another GTR at age 11 for
recurrent tumor. These resections were diagnosed as
residual/recurrent extraventricular neurocytoma. Surveil-
lance MRI at age 15 showed new nodular enhancement in
the resection cavity (Fig. 1E), prompting a third GTR for
recurrent disease. This most recent specimen showed
regions resembling the original tumor (Fig. 1F). However,
other areas showed high-grade features with histology that
closely resembled anaplastic oligodendroglioma (Fig. 1G).
This included hypercellular sheets of cells with rounded
nuclei and perinuclear cytoplasmic clearing, microvascular
proliferation, palisading necrosis, and up to 13 mitotic fig-
ures per 10 high power fields. ATRX immunohistochemis-
try showed loss of nuclear staining in the high-grade
regions of tumor (Fig. 1H), and ATRX expression was
retained in the low-grade portion. Additional immunohis-
tochemistry showed scattered neurofilament-positive pro-
cesses, scattered neuronal nuclear antigen-positive cells,
and CD34 staining of vascular endothelial cells only. The
Ki-67 labeling index was less than 2% in low-grade areas,
and up to 20% in high-grade areas. Oligodendrocyte tran-
scription factor 2 (OLIG2) was strongly positive in the
tumor cells in both areas. This feature argued against a
neurocytic neoplasm, and taken with the unusual clinical
history and high-grade histology, prompted additional
molecular studies and reconsideration of the initial
diagnosis.
Ancillary studies included fluorescence in situ hybridi-
zation (FISH) for 1p/19q, which showed codeletion limited
to the high-grade areas (Fig. 1I). Sanger sequencing of the
genes for isocitrate dehydrogenase 1 (IDH1), IDH2,
human histone 3.3 (H3F3A) was negative for mutations.
No BRAF fusions were detected by FISH. To clarify the
diagnosis and the relationship between the high-grade
specimen and the previous low-grade neoplasm, next-
generation sequencing (NGS) studies were performed on
tumor samples from the initial resection, the second recur-
rence, and the third recurrence which included the high-
grade histology. The UCSF 500 Cancer Gene Panel is a
hybrid capture-based NGS platform assessing mutation
status of over 500 cancer-associated genes, common gene
fusions, and whole-genome copy number profiling.10 This
analysis showed an FGFR1 kinase domain internal tandem
duplication, with identical duplication breakpoints seen in
all three specimens (Fig. 1J, 50 duplication boundary
within exon 10 and 30 duplication boundary within introns
18-19). This alteration is predicted to result in an in-frame
tandem duplication of FGFR1 codons 438-795, containing
the intracellular tyrosine kinase domain.11 Sequencing also
identified a p.R1427fs truncating ATRX mutation only in
the third recurrence specimen, with a mutant allele fre-
quency of 22%. The ATRX mutant allele was not detected
in the previous specimens, with 408 reads at this locus
from the initial resection specimen and 503 reads from the
second recurrence specimen. Whole-genome copy number
profiling of the most recent specimen showed complete
loss of chromosome arm 1p, but only partial loss of chro-
mosome arm 19q, not the whole-arm codeletion that is a
required component for an integrated diagnosis of
oligodendroglioma (Fig. 1K). A few distinct copy number
alterations were seen across the three specimens, but the
only shared abnormality other than FGFR1 internal
tandem duplication was monosomy 22q. Integrating the
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Fig. 1 MRI findings of the brain (A, E), histopathological observations on the tumor sections stained with H&E (B, C, F, G) and
immunohistochemical observations (D, H), FISH analysis of the tumor (I), and gene analyses of the tumor (J, K). The tumor is
located at the left temporal lobe detected on T1-weighted post-contrast coronal views at 3 years old (A) and 15 years old (E), prior
to the most recent GTR. New nodular enhancement appears at the resection cavity (E, arrow). Histological examinations on
H&E-stained sections show neurocytic cells, rosettes (B, inset), a mucoid background, and piloid features with elongated nuclei at
3 years old (B, C) and at the initial resection. The most recent GTR tissue shows low-grade and high-grade features (F, G). Syn-
aptophysin immunoreactivity is detected in the initial resection tissue (D), while ATRX immunoreactivity is undetectable in the
most recent GTR tissue (H). FISH analysis shows the results consistent with 1p/19q codeletion in the high-grade areas (I). Sequenc-
ing traces of the most recent GTR tissue shows 5 duplication boundary within exon 10 and 3 duplication boundary within introns
18-19 (J). Whole-genome copy number profiling on the most recent GTR tissue shows whole-arm 1p loss and only partial loss of
chromosome arm 19q (asterisks) and focal copy number gain on chromosome 8 representing FGFR1 kinase domain tandem duplica-
tion (red arrow). Scale bars: 100 μm (A–H).
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molecular and histologic findings across all of these speci-
mens, a revised diagnosis of high-grade neoplasm, most
consistent with anaplastic RGNT was rendered. The
patient has since completed a course of radiation therapy.
She experienced a temporary increase in seizure activity,
but is otherwise well, and surveillance imaging has not
identified tumor recurrence at approximately 11 months
after the most recent resection.
DISCUSSION
The conservation of the FGFR1 kinase domain internal
tandem duplication establishes this patient’s case as a sin-
gle tumor with multiple recurrences over approximately
14 years before undergoing spontaneous (i.e. without radi-
ation therapy) anaplastic progression. After review of mul-
tiple specimens and external review, this tumor was
determined to be most consistent with RGNT. Other enti-
ties were considered in the differential diagnosis, including
DNET and extraventricular neurocytoma. The initial diag-
nosis of extraventricular neurocytoma with a focal DNET-
like pattern was excluded largely on the basis of strongly
positive OLIG2 immunohistochemistry which was not
available at our institution at the time of the initial diagno-
sis. DNET is a more difficult entity to definitively exclude,
given the morphologic overlap with RGNT. However, the
findings of distinctly synaptophysin-positive neurocytic
rosettes and areas with elongated cells with piloid pro-
cesses are more typically seen in RGNT than DNET. The
lack of conventional DNET cytologic and architectural
features in any specimen such as floating neurons,
nodularity, and a columnar organization to the
glioneuronal element also argue against DNET and favor
RGNT. While criteria for anaplastic RGNT are not
defined, the presence of numerous mitotic figures, necro-
sis, and microvascular proliferation support the designa-
tion of anaplastic change in this particular case.
Targeted NGS has been shown to be of great benefit
in the pediatric neuro-oncology population, and in this
case NGS results helped to arrive at a more precise diag-
nosis and provided an explanation for the unusual con-
stellation of ATRX loss, wild-type IDH1 and IDH2, and
apparent 1p/19q-codeletion by FISH. The 1p/19q-
codeletion in this setting introduced pediatric-type
oligodendroglioma into the differential diagnosis,
although this codeletion is seen in only a minority of
pediatric-type oligodendrogliomas and they are predomi-
nantly low grade.12 Subsequent identification of only par-
tial loss of 19q by whole-genome copy number profiling
illustrates that methodologies for detection of whole-arm
1p and 19q loss should be considered as an adjunct to
1p/19q codeletion by FISH when apparent codeletion is
unaccompanied by IDH mutation. The finding of ATRX
immunohistochemistry loss limited to high-grade regions
of this tumor, accompanied by a confirmed ATRX muta-
tion, suggests that RGNT may be another tumor in which
ATRX gene mutation could be a potential driver of ana-
plastic progression. Finally, this case shows that the diag-
nosis of RGNT should not necessarily be restricted by
anatomic location despite a preponderance of cases
occurring near the fourth ventricle. A tumor with distinct
neurocytic and piloid components and appropriate muta-
tions such as PIK3CA or FGFR1 should prompt consid-
eration of the diagnosis regardless of location. While the
behavior of RGNTs is thought to be relatively indolent,
anaplastic progression can occur even in the absence of
radiation therapy.
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